EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSBSLG00000000958
Gene Symbol: PSMD6
3 Cross references
213 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSBSLG00000022582
Gene Symbol: PSMD7
3 Cross references
236 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSBSLG00000026670
Gene Symbol: PSMD8
3 Cross references
213 Possible Orthologues:

Proteasome Subunit Alpha Type-4

Ensembl ID : ENSBSLG00000019932
Gene Symbol: LOC114857893
3 Cross references
199 Possible Orthologues:

Proteasome Subunit Alpha Type-6

Ensembl ID : ENSBSLG00000021946
Gene Symbol: LOC114850083
3 Cross references
262 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSBSLG00000008746
Gene Symbol: PSMB11
1 Cross references
170 Possible Orthologues:

Proteasome Subunit Beta Type-11-Like

Ensembl ID : ENSBSLG00000003419
Gene Symbol: LOC114852947
3 Cross references
161 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSBSLG00000008741
Gene Symbol: LOC114844604
3 Cross references
223 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSBSLG00000002658
Gene Symbol: LOC114866991
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSBSLG00000002773
Gene Symbol: LOC114866992
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSBSLG00000005008
Gene Symbol: LOC114867229
3 Cross references
201 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSBSLG00000013381
Gene Symbol: LOC114866176
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).